Darwish, S., Elzawawy, A., Suliman, M., Mostafa, F. (2023). Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy at Suez Canal University Hospital, Ismailia, Egypt. Suez Canal University Medical Journal, 26(7), 10-18. doi: 10.21608/scumj.2023.320871
Salma Darwish; Ahmed M. Elzawawy; Marwa Suliman; Fifi E. Mostafa. "Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy at Suez Canal University Hospital, Ismailia, Egypt". Suez Canal University Medical Journal, 26, 7, 2023, 10-18. doi: 10.21608/scumj.2023.320871
Darwish, S., Elzawawy, A., Suliman, M., Mostafa, F. (2023). 'Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy at Suez Canal University Hospital, Ismailia, Egypt', Suez Canal University Medical Journal, 26(7), pp. 10-18. doi: 10.21608/scumj.2023.320871
Darwish, S., Elzawawy, A., Suliman, M., Mostafa, F. Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy at Suez Canal University Hospital, Ismailia, Egypt. Suez Canal University Medical Journal, 2023; 26(7): 10-18. doi: 10.21608/scumj.2023.320871
Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy at Suez Canal University Hospital, Ismailia, Egypt
Department of Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Abstract
Background: Limited studies measured the proportion of persistent ovarian escape (OE) in breast cancer patients on ovarian suppression (OS) therapy. Aim: To investigate persistent OE in premenopausal breast cancer patients on OS therapy and its correlation to clinical data and early clinical outcomes. Methods: This was a retrospective study, evaluating the percentage of persistent OE in premenopausal women on OS therapy within 3, 6, 9, 12, and 18 months of goserelin acetate injections. Demographic data, histopathological, hormonal receptor status, stage, and treatment received were retrieved from files of 143 eligible patients attending the Clinical Oncology and Nuclear Medicine department, Suez Canal University, Hospitals, Ismailia, Egypt. Blood Hormonal levels were assessed quarterly for the first year and then after 6 months. Results: 88 (61%) patients showed OE within the first 3 months. The OE group was significantly younger than the OS group (mean age 38.26 and 42.47 years for OE and OS group, respectively) (p value <0.001). The mean BMI was higher in the OE group (32.8 kg/m2) compared to the OS group (31.2 kg/m2) and was statistically significant (p value 0.020). Rates of ovarian escape were significantly higher in women who were receiving aromatase inhibitor versus tamoxifen (94.7% vs. 49.5%) (p value <0.001). Also, OE group has slightly lower disease-free survival compared to OS group. Conclusions: A significant percentage of patients did not achieve OS after 3 months of OS therapy. That was associated with younger age and higher BMI. OS was slightly better regarding disease-free survival than OE group.
View on SCiNiTO
Top